<![CDATA[Vifor Pharma Group 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=33088>Sat, 18 Apr 2026 15:12:05 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Extension of the postponement of the settlement of Vifor Pharma tender offer]]>https://www.newswire.co.kr/newsRead.php?no=947851Wed, 13 Jul 2022 16:45:00 +0900<![CDATA[Update on the timeline for Vifor Pharma tender offer]]>https://www.newswire.co.kr/newsRead.php?no=944450Fri, 13 May 2022 10:00:00 +0900<![CDATA[Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients]]>https://www.newswire.co.kr/newsRead.php?no=943634Thu, 28 Apr 2022 15:30:00 +0900<![CDATA[94th Vifor Pharma Group Annual General Meeting]]>https://www.newswire.co.kr/newsRead.php?no=943562Wed, 27 Apr 2022 17:25:00 +0900<![CDATA[DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy]]>https://www.newswire.co.kr/newsRead.php?no=942146Mon, 04 Apr 2022 14:10:00 +0900<![CDATA[Publication of definitive end result for Vifor Pharma tender offer]]>https://www.newswire.co.kr/newsRead.php?no=941742Mon, 28 Mar 2022 15:00:00 +0900<![CDATA[Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent]]>https://www.newswire.co.kr/newsRead.php?no=941528Wed, 23 Mar 2022 16:40:00 +0900<![CDATA[Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful]]>https://www.newswire.co.kr/newsRead.php?no=940709Tue, 08 Mar 2022 17:05:00 +0900<![CDATA[Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent]]>https://www.newswire.co.kr/newsRead.php?no=940482Thu, 03 Mar 2022 17:30:00 +0900<![CDATA[Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients]]>https://www.newswire.co.kr/newsRead.php?no=940256Mon, 28 Feb 2022 15:40:00 +0900<![CDATA[Vifor Pharma appoints two new members to the Executive Committee]]>https://www.newswire.co.kr/newsRead.php?no=938936Thu, 03 Feb 2022 09:35:00 +0900<![CDATA[VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis]]>https://www.newswire.co.kr/newsRead.php?no=938413Thu, 20 Jan 2022 10:00:00 +0900<![CDATA[Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®]]>https://www.newswire.co.kr/newsRead.php?no=936949Tue, 21 Dec 2021 17:30:00 +0900<![CDATA[Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation]]>https://www.newswire.co.kr/newsRead.php?no=936851Mon, 20 Dec 2021 15:40:00 +0900<![CDATA[Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma]]>https://www.newswire.co.kr/newsRead.php?no=936679Thu, 16 Dec 2021 15:30:00 +0900<![CDATA[CSL Limited announces tender offer to acquire Vifor Pharma Ltd]]>https://www.newswire.co.kr/newsRead.php?no=936498Tue, 14 Dec 2021 17:05:00 +0900<![CDATA[Vifor Pharma comments on media speculation]]>https://www.newswire.co.kr/newsRead.php?no=936399Mon, 13 Dec 2021 17:31:28 +0900<![CDATA[First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease]]>https://www.newswire.co.kr/newsRead.php?no=936367Mon, 13 Dec 2021 14:35:00 +0900<![CDATA[Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee]]>https://www.newswire.co.kr/newsRead.php?no=936277Fri, 10 Dec 2021 16:25:00 +0900<![CDATA[Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury]]>https://www.newswire.co.kr/newsRead.php?no=936275Fri, 10 Dec 2021 16:20:00 +0900<![CDATA[Vifor Pharma comments on market speculations]]>https://www.newswire.co.kr/newsRead.php?no=935750Fri, 03 Dec 2021 11:50:00 +0900<![CDATA[Vifor Pharma announces changes to the Executive Committee as CFO retires]]>https://www.newswire.co.kr/newsRead.php?no=935457Tue, 30 Nov 2021 15:36:52 +0900<![CDATA[Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis]]>https://www.newswire.co.kr/newsRead.php?no=935297Fri, 26 Nov 2021 15:30:00 +0900<![CDATA[Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG]]>https://www.newswire.co.kr/newsRead.php?no=934948Mon, 22 Nov 2021 15:50:00 +0900<![CDATA[VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis]]>https://www.newswire.co.kr/newsRead.php?no=934316Fri, 12 Nov 2021 15:35:00 +0900